Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74:477–95.
Google Scholar
Lo P-K, Sukumar S. Epigenomics and breast cancer. Pharmacogenomics. 2008;9:1879–902.
Google Scholar
Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S, et al. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene. 2000;19:1556–63.
Google Scholar
Hua S, Kittler R, White KPA. Genomic mechanism for antagonism between retinoic acid and estrogen signaling in breast cancer. Cell. 2009;137:1259–71.
Google Scholar
Centritto F, Paroni G, Bolis M, Garattini SK, Kurosaki M, Barzago MM, et al. Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: luminal phenotype and RARα expression. EMBO Mol Med. 2015;7:950–72.
Google Scholar
Costantini L, Merendino N. Polyunsaturated fatty acids and microbiota relationship: implications in cancer onset and treatment. J Clin Med. 2020;9:3490.
Google Scholar
Caricasulo MA, Zanetti A, Terao M, Garattini E, Paroni G. Cellular and micro-environmental responses influencing the antitumor activity of all-trans retinoic acid in breast cancer. Cell Commun Signal. 2024;22:127.
Google Scholar
Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer. 2001;1:181–93.
Google Scholar
Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000;14:121–41.
Google Scholar
Connolly RM, Nguyen NK, Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res. 2013;19:1651–59.
Google Scholar
Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–21.
Google Scholar
Garattini E, Bolis M, Garattini SK, Fratelli M, Centritto F, Paroni G, et al. Retinoids and breast cancer: from basic studies to the clinic and back again. Cancer Treat Rev. 2014;40:739–49.
Google Scholar
Coyle KM, Dean CA, Thomas ML, Vidovic D, Giacomantonio CA, Helyer L, et al. DNA methylation predicts the response of triple-negative breast cancers to all-trans retinoic acid. Cancers. 2018;10:397.
Google Scholar
Choi W-S, Liu R-Z, Mak C, Maadi H, Godbout R. Overcoming retinoic acid resistance in HER2-enriched breast cancers: role of MYC. FEBS J. 2024;291:3521–38.
Google Scholar
Augimeri G, Bonofiglio D. PPARgamma: a potential intrinsic and extrinsic molecular target for breast cancer therapy. Biomedicines. 2021;9:543.
Google Scholar
Augimeri G, Giordano C, Gelsomino L, Plastina P, Barone I, Catalano S, et al. The role of pparγ ligands in breast cancer: from basic research to clinical studies. Cancers. 2020;12:2623.
Google Scholar
Xu H, Liu Z, Shi H, Wang C. Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20:1051.
Google Scholar
Vanhevel J, Verlinden L, Doms S, Wildiers H, Verstuyf A. The role of vitamin D in breast cancer risk and progression. Endocr Relat Cancer. 2022;29:R33–R55.
Google Scholar
Liu Y-Y, Brent GA. Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation. Trends Endocrinol Metab. 2010;21:166–73.
Google Scholar
Zehni AZ, Batz F, Vattai A, Kaltofen T, Schrader S, Jacob S-N, et al. The prognostic impact of retinoid X receptor and thyroid hormone receptor alpha in unifocal vs. multifocal/multicentric breast cancer. Int J Mol Sci. 2021;22:957.
Google Scholar
Feng H, Zhang Y-B, Gui J-F, Lemon SM, Yamane D. Interferon regulatory factor 1 (IRF1) and anti-pathogen innate immune responses. PLoS Pathog. 2021;17:e1009220.
Google Scholar
Oh Y-T, Yue P, Wang D, Tong J-S, Chen ZG, Khuri FR, et al. Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling. Oncotarget. 2015;6:41324–38.
Google Scholar
Yuan X, Gajan A, Chu Q, Xiong H, Wu K, Wu GS. Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer Metastasis Rev. 2018;37:733–48.
Google Scholar
Brown G. Deregulation of all-trans retinoic acid signaling and development in cancer. Int J Mol Sci. 2023;24:12089.
Google Scholar
Temian DC, Pop LA, Irimie AI, Berindan-Neagoe I. The epigenetics of triple-negative and basal-like breast cancer: current knowledge. J Breast Cancer. 2018;21:233–43.
Google Scholar
Zhou Y, Liu H, Hong W, Su H, Mu Y, Cheng Y, et al. Epigenetic regulation espeically histone modifications in breast cancer: a viable and emerging targeted therapeutic strategy. J Cancer. 2025;16:4037–46.
Google Scholar
Babar Q, Saeed A, Tabish TA, Pricl S, Townley H, Thorat N. Novel epigenetic therapeutic strategies and targets in cancer. Biochim Biophys Acta Mol Basis Dis. 2022;1868:166552.
Google Scholar
Otmani K, Lewalle P. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front Oncol. 2021;11:708765.
Google Scholar
Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y. Long non-coding RNA: a new player in cancer. J Hematol Oncol. 2013;6:37.
Google Scholar
Hashemi M, Fard AA, Pakshad B, Asheghabadi PS, Hosseinkhani A, Hosseini AS, et al. Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: recent insights and potential clinical applications. Noncoding RNA Res. 2024;11:1–21.
Google Scholar
Jan N, Sofi S, Qayoom H, Haq BU, Shabir A, Mir MA. Targeting breast cancer stem cells through retinoids: a new hope for treatment. Crit Rev Oncol Hematol. 2023;192:104156.
Google Scholar
Zhang Z, Joh K, Yatsuki H, Zhao W, Soejima H, Higashimoto K, et al. Retinoic acid receptor beta2 is epigenetically silenced either by DNA methylation or repressive histone modifications at the promoter in cervical cancer cells. Cancer Lett. 2007;247:318–27.
Google Scholar
Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 2002;62:2455–61.
Google Scholar
Liu X, Nugoli M, Laferrière J, Saleh SM, Rodrigue-Gervais IG, Saleh M, et al. Stromal retinoic acid receptor beta promotes mammary gland tumorigenesis. Proc Natl Acad Sci USA. 2011;108:774–79.
Google Scholar
Rossetti S, Sacchi N. Emerging cancer epigenetic mechanisms regulated by all-trans retinoic acid. Cancers. 2020;12:2275.
Google Scholar
Merino VF, Nguyen N, Jin K, Sadik H, Cho S, Korangath P, et al. Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple-negative breast cancer. Cancer Res. 2016;76:2013–24.
Google Scholar
Mongan NP, Gudas LJ. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2’-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Mol Cancer Ther. 2005;4:477–86.
Google Scholar
Merino VF, Cho S, Nguyen N, Sadik H, Narayan A, Talbot C, et al. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer. Breast Cancer Res. 2018;20:145.
Google Scholar
Schug TT, Berry DC, Shaw NS, Travis SN, Noy N. Dual transcriptional activities underlie opposing effects of retinoic acid on cell survival. Cell. 2007;129:723–33.
Google Scholar
Schug TT, Berry DC, Toshkov IA, Cheng L, Nikitin AY, Noy N. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. Proc Natl Acad Sci USA. 2008;105:7546–51.
Google Scholar
Dobrotkova V, Chlapek P, Mazanek P, Sterba J, Veselska R. Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy. BMC Cancer. 2018;18:1059.
Google Scholar
Costantini L, Molinari R, Farinon B, Merendino N. Retinoic acids in the treatment of most lethal solid cancers. J Clin Med. 2020;9:360.
Google Scholar
Xue X, Li Z, Zhao J, Zhao Z, Li Z, Li Y, et al. Advances in the relationship between AP-1 and tumorigenesis, development and therapy resistance. Discov Oncol. 2025;16:61.
Google Scholar
Lin F, Kolluri SK, Chen G, Zhang X. Regulation of retinoic acid-induced inhibition of AP-1 activity by orphan receptor chicken ovalbumin upstream promoter-transcription factor. J Biol Chem. 2002;277:21414–22.
Google Scholar
Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18:605–11.
Google Scholar
Vinckier NK, Patel NA, Geusz RJ, Wang A, Wang J, Matta I, et al. LSD1-mediated enhancer silencing attenuates retinoic acid signalling during pancreatic endocrine cell development. Nat Commun. 2020;11:2082.
Google Scholar
Liu J, Feng J, Li L, Lin L, Ji J, Lin C, et al. Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer. EMBO Rep. 2020;21:e48597.
Google Scholar
Varisli L, Zoumpourlis P, Spandidos DA, Zoumpourlis V, Vlahopoulos S. ALDH1A1 in breast cancer: a prospective target to overcome therapy resistance (Review). Oncol Lett. 2025;29:213.
Google Scholar
Wang Q, Jiang J, Ying G, Xie X-Q, Zhang X, Xu W, et al. Tamoxifen enhances stemness and promotes metastasis of ERα36+ breast cancer by upregulating ALDH1A1 in cancer cells. Cell Res. 2018;28:336–58.
Google Scholar
Yue H, Hu Z, Hu R, Guo Z, Zheng Y, Wang Y, et al. ALDH1A1 in cancers: bidirectional function, drug resistance, and regulatory mechanism. Front Oncol. 2022;12:918778.
Google Scholar
Lavudi K, Nuguri SM, Olverson Z, Dhanabalan AK, Patnaik S, Kokkanti RR. Targeting the retinoic acid signaling pathway as a modern precision therapy against cancers. Front Cell Dev Biol. 2023;11:1254612.
Google Scholar
Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 1990;348:699–704.
Google Scholar
Tobin RP, Jordan KR, Davis D, McCarter M. Effects of in vitro ATRA treatment on human MDSC expansion and function. J Clin Oncol. 2017;35:125–25.
Google Scholar
Olson DJ, Luke JJ. Myeloid maturity: ATRA to enhance Anti-PD-1? Clin Cancer Res. 2023;29:1167–69.
Google Scholar
Tobin RP, Jordan KR, Robinson WA, Davis D, Borges VF, Gonzalez R, et al. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018;63:282–91.
Google Scholar
Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos IM, Taverna F, et al. Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of antiangiogenic therapy. Cancer Res. 2018;78:3220–32.
Google Scholar
Rao E, Hou Y, Huang X, Wang L, Wang J, Zheng W, et al. All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Sci Immunol. 2021;6:eaba8426.
Google Scholar
He H, Zheng Y, Ji J, Ye C, Sun Y, Peng Y, et al. Liposomal all-trans retinoic acid boosts anti-tumor immunity of radiotherapy via mitigating cancer stemness and remedying tumor microenvironment. J Control Release. 2025;385:113995.
Google Scholar
Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19:2456–71.
Google Scholar
Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999;91:1847–56.
Google Scholar
Aristarco V, Serrano D, Maisonneuve P, Guerrieri-Gonzaga A, Lazzeroni M, Feroce I, et al. Fenretinide in young women at genetic or familial risk of breast cancer: a placebo-controlled biomarker trial. Cancer Prev Res. 2024;17:255–63.
Google Scholar
Nagai Y, Ambinder AJ. The promise of retinoids in the treatment of cancer: neither burnt out nor fading away. Cancers. 2023;15:3535.
Google Scholar
Rossetti S, Ren M, Visconti N, Corlazzoli F, Gagliostro V, Somenzi G, et al. Tracing anti-cancer and cancer-promoting actions of all-trans retinoic acid in breast cancer to a RARα epigenetic mechanism of mammary epithelial cell fate. Oncotarget. 2016;7:87064–80.
Google Scholar
Ross-Innes CS, Stark R, Holmes KA, Schmidt D, Spyrou C, Russell R, et al. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev. 2010;24:171–82.
Google Scholar
Johansson HJ, Sanchez BC, Mundt F, Forshed J, Kovacs A, Panizza E, et al. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun. 2013;4:2175.
Google Scholar
Goel N, Yadegarynia S, Lubarsky M, Choi S, Kelly K, Balise R, et al. Racial and ethnic disparities in breast cancer survival: emergence of a clinically distinct hispanic black population. Ann Surg. 2021;274:e269–75.
Google Scholar
Ho PJ, Dorajoo R, Ivanković I, Ong SS, Khng AJ, Tan BK-T, et al. DNA methylation and breast cancer-associated variants. Breast Cancer Res Treat. 2021;188:713–27.
Google Scholar
Founta K, Chambwe N. Genetic ancestry-specific meQTLs control immune function regulation in a breast cancer cohort of African and European patients. 2024, https://doi.org/10.1101/2024.08.29.610316.
Lou S, Gao H, Hong H, Zhu Z, Zhao H. Inhibition of retinoic acid receptor α phosphorylation represses the progression of triple-negative breast cancer via transactivating miR-3074-5p to target DHRS3. J Exp Clin Cancer Res. 2021;40:141.
Google Scholar
Wu W, Warner M, Wang L, He W-W, Zhao R, Guan X, et al. Drivers and suppressors of triple-negative breast cancer. Proc Natl Acad Sci USA. 2021;118:e2104162118.
Google Scholar
McKeown MR, Corces MR, Eaton ML, Fiore C, Lee E, Lopez JT, et al. Superenhancer analysis defines novel epigenomic subtypes of non-APL AML, including an RARα dependency targetable by SY-1425, a potent and selective RARα agonist. Cancer Discov. 2017;7:1136–53.
Google Scholar
Schenk T, Zadegan FG, Fiedler F, Stanko C, Ölsner L, Schuett J, et al. LSD1 and GCN5 inhibition facilitates Am80 (tamibarotene)-mediated differentiation therapy in RARA-high non-APL AML. https://doi.org/10.21203/rs.3.rs-4791108/v1 2024.
Tayari MM, Santos HGD, Kwon D, Bradley TJ, Thomassen A, Chen C, et al. Clinical responsiveness to all-trans retinoic acid is potentiated by LSD1 inhibition and associated with a quiescent transcriptome in myeloid malignancies. Clin Cancer Res. 2021;27:1893–903.
Google Scholar
